These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 15316868)

  • 1. A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial.
    Kushida K; Fukunaga M; Kishimoto H; Shiraki M; Itabashi A; Inoue T; Kaneda K; Morii H; Nawata H; Yamamoto K; Ohashi Y; Orimo H
    J Bone Miner Metab; 2004; 22(5):469-78. PubMed ID: 15316868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
    Fukunaga M; Kushida K; Kishimoto H; Shiraki M; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H;
    Osteoporos Int; 2002 Dec; 13(12):971-9. PubMed ID: 12459940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
    Seibel MJ; Naganathan V; Barton I; Grauer A
    J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis.
    Storm T; Kollerup G; Thamsborg G; Genant HK; Sørensen OH
    J Rheumatol; 1996 Sep; 23(9):1560-4. PubMed ID: 8877926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.
    Eastell R; Barton I; Hannon RA; Chines A; Garnero P; Delmas PD
    J Bone Miner Res; 2003 Jun; 18(6):1051-6. PubMed ID: 12817758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.
    Brown JP; Kendler DL; McClung MR; Emkey RD; Adachi JD; Bolognese MA; Li Z; Balske A; Lindsay R
    Calcif Tissue Int; 2002 Aug; 71(2):103-11. PubMed ID: 12085156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.
    Storm T; Thamsborg G; Steiniche T; Genant HK; Sørensen OH
    N Engl J Med; 1990 May; 322(18):1265-71. PubMed ID: 2109197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old.
    Boonen S; McClung MR; Eastell R; El-Hajj Fuleihan G; Barton IP; Delmas P
    J Am Geriatr Soc; 2004 Nov; 52(11):1832-9. PubMed ID: 15507059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.
    Watts NB; Harris ST; Genant HK; Wasnich RD; Miller PD; Jackson RD; Licata AA; Ross P; Woodson GC; Yanover MJ
    N Engl J Med; 1990 Jul; 323(2):73-9. PubMed ID: 2113611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment.
    Bahlous A; Bouzid K; Sahli H; Sallami S; Abdelmoula J
    Tunis Med; 2009 Jun; 87(6):380-1. PubMed ID: 19927782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis.
    Ste-Marie LG; Sod E; Johnson T; Chines A
    Calcif Tissue Int; 2004 Dec; 75(6):469-76. PubMed ID: 15478000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis.
    Harrington JT; Ste-Marie LG; Brandi ML; Civitelli R; Fardellone P; Grauer A; Barton I; Boonen S
    Calcif Tissue Int; 2004 Feb; 74(2):129-35. PubMed ID: 14648009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup.
    Sato S; Ohosone Y; Suwa A; Yasuoka H; Nojima T; Fujii T; Kuwana M; Nakamura K; Mimori T; Hirakata M
    J Rheumatol; 2003 Dec; 30(12):2673-9. PubMed ID: 14719212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.
    Palomba S; Manguso F; Orio F; Russo T; Oppedisano R; Sacchinelli A; Falbo A; Tolino A; Zullo F; Mastrantonio P
    Menopause; 2008; 15(4 Pt 1):730-6. PubMed ID: 18698280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risedronate reduces the risk of first vertebral fracture in osteoporotic women.
    Heaney RP; Zizic TM; Fogelman I; Olszynski WP; Geusens P; Kasibhatla C; Alsayed N; Isaia G; Davie MW; Chesnut CH
    Osteoporos Int; 2002; 13(6):501-5. PubMed ID: 12107665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss.
    Adachi JD; Roux C; Pitt PI; Cooper C; Moniz C; Dequeker J; Ioannidis G; Cawley MI; Jenkins EA; Walker-Bone KE; Pack S; Stephenson GF; Laan RF; Brown J; Geusens P
    J Rheumatol; 2000 Oct; 27(10):2424-31. PubMed ID: 11036840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.
    Delmas PD; McClung MR; Zanchetta JR; Racewicz A; Roux C; Benhamou CL; Man Z; Eusebio RA; Beary JF; Burgio DE; Matzkin E; Boonen S
    Bone; 2008 Jan; 42(1):36-42. PubMed ID: 17920005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risedronate decreases bone resorption and improves low back pain in postmenopausal osteoporosis patients without vertebral fractures.
    Ohtori S; Akazawa T; Murata Y; Kinoshita T; Yamashita M; Nakagawa K; Inoue G; Nakamura J; Orita S; Ochiai N; Kishida S; Takaso M; Eguchi Y; Yamauchi K; Suzuki M; Aoki Y; Takahashi K
    J Clin Neurosci; 2010 Feb; 17(2):209-13. PubMed ID: 20044258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial.
    Hooper MJ; Ebeling PR; Roberts AP; Graham JJ; Nicholson GC; D'Emden M; Ernst TF; Wenderoth D
    Climacteric; 2005 Sep; 8(3):251-62. PubMed ID: 16390757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.